YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers.

In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575).

To be a reliable and respected IVD enterprise, YHLO has put extensive investments in R&D and firmly associated with the top-tier universities, medical schools and research institutions worldwide on scientific studies. With over a decade's continuous development expertise in immunoassays solution, YHLO may provide a broad range of instruments (based on Chemiluminescence, ELISA, Immunoblot and Immunofluorescnce methodologies) with patented technologies and outstanding features, as well as a comprehensive total solutions with portfolios in fertility and reproductive health, diabetes, infectious diseases, autoimmune disorders and other novel assays on rare diseases analysis.

YHLO thanks to its premium quality management has been certified by international standards, ISO 9001:2015, ISO 13485:2016, KGMP of Korea, TGA of Australia, etc. To date, YHLO has a global presence by nearly 100 countries around the world, our strategic alliances with multinational corporations enable us to be more competitive. Moreover, YHLO has in-depth cooperation with oversea research partners in Europe, USA, Japan and Australia, with aim of developing advanced technologies and create more medical value for health and vitality of people all over the world.

YHLO will continue its efforts toward the mission “Focus on Healthcare, Better Life with Technology”.